Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by BlueFranky on Feb 17, 2023 5:14pm

Question

If you look at the table in the presentation Eog posted from the conference - they show 8 CR and 3 IR

then show a total of 12 TR

 So could somebody please explain?
Comment by consultant99 on Feb 17, 2023 5:16pm
Looks like someone screwed up...typo not caught. Not good form to make mistakes in presentations 
Comment by N0taP00p on Feb 17, 2023 7:38pm
IF there is no better explanation, then this inability to do basic math AND lack of due diligence for critical presentations like this is shocking.  No wonder it takes Eoganacht and Enriquesuave to reinterpret everything they publish. You CANNOT sweep this kind of thing quietly under the rug. I can understand the miscalculation of bladder volumes as a one time thing.  But not 8+3 =12 ...more  
Comment by Rumpl3StiltSkin on Feb 18, 2023 11:29am
Poop, I think the FDA has probably seen this sort of thing many many times before. I'm not worried that things started a bit rocky. I think Eoga's observations about the 'Real' CR %'s will also be fully evaluated by FDA in TLT's favor.
Comment by CancerSlayer on Feb 20, 2023 3:11am
The percentages reported are correct, which is what's ultimately considered/remembered by meeting attendees.  There should be no such typos made for the AUA meeting.  Interestingly, that dreaded "12" continues to haunt all of us ; ).  All imo...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250